Study guide

9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia

Neonatal Pediatric Transport C-NPT

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The C-NPT Exam

About the C-NPT Exam: 2026 Format, Eligibility & Content Outline

2 Chapter 1: Transport Systems, Regulatory Framework & Legal Issues

1.1 Transport System Architecture, Accreditation (CAMTS) & Dispatch Triage 1.2 Regulatory & Legal Mandates: EMTALA, HIPAA, Consent & Documentation 1.3 Medical Direction, Scope of Practice & Ethical Considerations

3 Chapter 2: Safety, Communication, Crew Resource Management & Transport Environment

2.1 Crew Resource Management (CRM), Situational Awareness & Sterile Cockpit 2.2 Aircraft & Ground Ambulance Operations, Landing Zones & Vehicle Dynamics 2.3 Environmental Hazards, Weather Minimums & In-Flight Emergency Procedures 2.4 Communication in Transport: Peer Handoffs, Age-Appropriate Care, Families & Crew Stressors 2.5 Infection Control, PPE, Scene Safety & Disaster/Evacuation Planning

4 Chapter 3: Flight Physiology & Environmental Stressors

3.1 Physical Gas Laws & Transport Implications (Boyle, Dalton, Charles, Henry, Graham) 3.2 Altitude Hypoxia, Barometric Pressure Changes & Dysbarism 3.3 Acceleration Forces (G-forces), Vibration & Acoustic Stress in Transit 3.4 Thermoregulation Physics & Neutral Thermal Environment in Transit

5 Chapter 4: Invasive Procedures & Transport Monitoring

4.1 Advanced Airway Management & Endotracheal Intubation in Transit 4.2 Pleural Decompression (Needle Thoracostomy & Chest Tube Management) 4.3 Vascular Access: Umbilical Lines (UAC/UVC), Intraosseous (IO) & Arterial Lines

6 Chapter 5: Transport Equipment, Respiratory Physiology & Mechanical Ventilation

5.1 Transport Incubators (Isolettes), Thermal Control & Electrical/Gas Power Systems 5.2 Portable Ventilators & Modes (PC, VC, PRVC, High Frequency) 5.3 Gas Cylinder Duration Calculations, Oxygen Delivery & Inhaled Nitric Oxide (iNO) 5.4 Respiratory Physiology: Acid-Base Balance, Oxygenation, Lung Mechanics & Troubleshooting

7 Chapter 6: Transport Pharmacology, Resuscitation, Fluids & Electrolytes

6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone) 6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport 6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy 6.4 Resuscitation Protocols (NRP, PALS) & Shock Fluid Resuscitation 6.5 Antimicrobial Pharmacology in Neonatal & Pediatric Transport 6.6 Post-Resuscitation Care, Defibrillation & Cardioversion in Transit, ECMO Indications & the Transport-vs-Stay Decision 6.7 Fluid & Electrolyte Therapy Across the Ages: Maintenance, Dehydration, Fluid Overload & Electrolyte Emergencies

8 Chapter 7: Neonatal Respiratory Pathologies & Management

7.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN) 7.3 Transient Tachypnea (TTN), Neonatal Pneumothorax & Congenital Diaphragmatic Hernia (CDH) 7.4 Neonatal Upper Airway Anomalies, Aspiration, Pneumonia, Chronic Lung Disease & Respiratory Failure

9 Chapter 8: Neonatal Cardiovascular Critical Care

8.1 Ductal-Dependent Cyanotic Congenital Heart Defects (TGA, TOF, Tricuspid Atresia) 8.2 Ductal-Dependent Systemic Blood Flow Lesions (HLHS, Coarctation, Interrupted Arch) 8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care 8.4 Acyanotic Congenital Heart Lesions, Patent Ductus Arteriosus, Obstructed TAPVR & Neonatal Heart Failure

10 Chapter 9: Neonatal Neurological & Metabolic Crises

9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia 9.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia 9.4 Subgaleal Hemorrhage, Neonatal Sepsis & Meningitis, and Perinatal Substance Exposure (NOWS)

11 Chapter 10: Neonatal Surgical Emergencies, Neural Tube Defects & ELBW Care

10.1 Abdominal Wall Defects (Gastroschisis vs. Omphalocele) & TEF/Esophageal Atresia 10.2 Necrotizing Enterocolitis (NEC), Malrotation with Volvulus & Intestinal Obstruction 10.3 Care of the Extremely Low Birth Weight (ELBW) Infant (<1000g) in Transit 10.4 Neural Tube Defects: Myelomeningocele, Encephalocele & Transport of the Newborn With an Open Spinal Defect

12 Chapter 11: Pediatric Respiratory Emergencies

11.1 Acute Upper Airway Obstruction (Croup, Epiglottitis, Bacterial Tracheitis, Foreign Body) 11.2 Lower Airway Crises: Status Asthmaticus & Severe Bronchiolitis 11.3 Pediatric Acute Respiratory Distress Syndrome (PARDS) & Severe Pneumonia

13 Chapter 12: Pediatric Shock & Cardiovascular Crises

12.1 Pathophysiology & Transport Management of Pediatric Septic Shock 12.2 Hypovolemic, Cardiogenic & Anaphylactic Shock in Children 12.3 Pediatric Cardiac Emergencies: SVT, Ventricular Arrhythmias & Myocarditis 12.4 Pediatric Cardiovascular Crises: Palliated Congenital Heart Disease, Pulmonary Hypertensive Crisis, Pericarditis & Tamponade, Hypertensive Emergency & Anterior Mediastinal Mass

14 Chapter 13: Pediatric Neurological Emergencies & Trauma

13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis 13.2 Pediatric Traumatic Brain Injury (TBI) & Increased Intracranial Pressure (ICP) 13.3 Blunt/Penetrating Trauma, Spinal Motion Restriction & Thermal Burns 13.4 Non-Accidental Trauma, Smoke Inhalation (Carbon Monoxide & Cyanide) & Heat Illness

15 Chapter 14: Pediatric Toxicological, Environmental & Endocrine Emergencies

14.1 Common Pediatric Toxic Ingestions, Poisonings & Antidotes 14.2 Diabetic Ketoacidosis (DKA) & Environmental Emergencies (Submersion, Hypothermia) 14.3 Button Battery & Foreign-Body Ingestions, Bites & Envenomations, and Hazardous-Material Exposures

16 Chapter 15: Pediatric Metabolic & Hematologic Emergencies

15.1 Anemia, Sickle Cell Disease, Coagulopathies & Blood Product Administration 15.2 Oncologic Emergencies, Acute Kidney Injury & Pediatric Electrolyte Crises

9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia

Key Takeaways Explain This Topic AI

Perinatal hypoxic-ischemic brain injury evolves across a triphasic continuum: primary energy failure during the acute insult, a 0-6 hour latent phase representing the critical therapeutic window, and secondary energy failure characterized by delayed cytotoxic edema, mitochondrial permeability pore opening, excitotoxicity, and neuronal apoptosis.

Therapeutic hypothermia eligibility requires a gestational age >= 35-36 weeks, postnatal age <= 6 hours, severe metabolic acidosis (cord or 1-hour blood gas pH <= 7.00 or base deficit >= 16 mmol/L), and moderate-to-severe encephalopathy (Sarnat Stage 2 or 3) or documented clinical seizures.

Transport cooling targets a core temperature of 33.5 °C (acceptable range 33.0 °C to 34.0 °C) monitored continuously via a securely placed rectal probe (2-3 cm depth) or mid-esophageal probe; peripheral and axillary skin measurements are strictly contraindicated due to intense peripheral vasoconstriction.

Uncontrolled passive cooling risks catastrophic overcooling (<32.0 °C), precipitating severe sinus bradycardia (<80 bpm), ventricular arrhythmias, refractory pulmonary hypertension (PPHN), platelet dysfunction, and severe coagulopathy; servo-controlled active cooling systems provide the safest, most stable thermal management in transit.

Last updated: September 2026

Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia

Hypoxic-ischemic encephalopathy (HIE) resulting from acute perinatal asphyxia is a primary cause of neonatal mortality and long-term neurodevelopmental impairment, including spastic cerebral palsy, sensorineural deafness, microcephaly, and cognitive deficits. Therapeutic hypothermia initiated within a strict six-hour therapeutic window provides robust neuroprotection by dampening secondary biochemical cascades. For the neonatal transport specialist, recognizing eligibility, establishing precise core temperature monitoring, initiating controlled cooling, and preventing the life-threatening consequences of uncontrolled overcooling are critical transport competencies.

Pathophysiology of Perinatal Asphyxia & Triphasic Brain Injury

Perinatal asphyxia occurs when severe impairment of placental or pulmonary gas exchange leads to progressive hypoxemia, hypercapnia, and metabolic acidosis. The resulting neurological injury does not occur as a single static event, but rather unfolds across a well-defined triphasic continuum.

1. Primary Energy Failure (Acute Insult)

During the primary sentinel asphyxial event (e.g., complete placental abruption, uterine rupture, umbilical cord prolapse, or sustained fetal terminal bradycardia), cerebral blood flow and oxygen delivery fall below critical thresholds.

Cellular Depolarization: Depletion of cellular oxygen halts mitochondrial oxidative phosphorylation, precipitating an immediate exhaustion of high-energy adenine nucleotides (adenosine triphosphate [ATP] and phosphocreatine [PCr]).

Ion Pump Arrest & Cytotoxic Edema: Loss of ATP deactivates the energy-dependent Na+/K+-ATPase and Ca2+-ATPase membrane pumps. Intracellular sodium, chloride, and water accumulate rapidly, causing acute cytotoxic edema, while massive membrane depolarization triggers unchecked extracellular glutamate accumulation and toxic calcium influx.

Lactic Acidosis: Anaerobic glycolysis ensues, generating intracellular lactic acid, tissue acidosis, and early cellular swelling.

2. The Latent Phase (The 0 to 6 Hour Window of Opportunity)

Following successful cardiopulmonary resuscitation and restoration of systemic perfusion, cerebral cellular metabolism partially normalizes. Phosphocreatine and ATP stores transiently recover, and microvascular blood flow temporarily stabilizes. This latent phase lasts approximately 6 hours .

The Critical Window: Although cells appear biochemically recovered, submicroscopic apoptotic signaling pathways have already been triggered. Therapeutic hypothermia must be initiated during this 6-hour latent window before secondary energy failure begins. Cooling applied after 6 hours fails to prevent downstream enzymatic activation and provides negligible neuroprotection.

3. Secondary Energy Failure (6 to 72+ Hours)

Beginning approximately 6 to 12 hours after the initial insult and peaking at 24 to 72 hours, secondary energy failure develops without any new hypoxic event:

Mitochondrial Permeability Transition Pore (mPTP) Opening: Massive calcium overload induces mitochondrial membrane collapse and release of cytochrome c into the cytoplasm.

Excitotoxicity & Free Radical Cascades: Excessive glutamate overactivates post-synaptic N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, releasing toxic reactive oxygen species (ROS), peroxynitrite, and nitric oxide.

Neuroinflammation & Apoptosis: Microglial activation and proinflammatory cytokine cascades (TNF-alpha, IL-1beta) activate caspase-3-dependent apoptotic and necrotic cell death pathways, leading to permanent cortical, basal ganglia, and thalamic necrosis.

Clinical Staging: Sarnat Criteria for Neonatal Encephalopathy

Clinical grading using the modified Sarnat and Sarnat staging system distinguishes mild encephalopathy from moderate and severe forms that warrant therapeutic hypothermia.

  • Clinical Assessment Parameter Sarnat Stage 1 (Mild) Sarnat Stage 2 (Moderate) Sarnat Stage 3 (Severe)
  • Level of Consciousness Hyperalert, irritable, jittery Lethargic, obtunded Stuporous, comatose

Neuromuscular Tone Normal or slightly hypertonic Distinct hypotonia (proximal > distal) Flaccid tone, completely absent resistance

  • Posture Mild distal flexion Moderate flexion, weak posture Decerebrate posturing or complete flaccidity
  • Primitive Reflexes: Suck Normal or weak Weak, uncoordinated, or absent Completely absent
  • Primitive Reflexes: Moro Exaggerated, low threshold Incomplete, weak, or absent Completely absent

Pupillary & Autonomic Function Dilated (mydriasis), sympathetic excess (tachycardia) Constricted (miosis), parasympathetic excess (bradycardia, copious secretions) Asymmetric, dilated, non-reactive to light; profound autonomic instability

Clinical Seizures Absent Frequent (focal, multifocal clonic, or subtle) Frequent, refractory, or electrographic burst suppression

Electroencephalogram (EEG / aEEG) Normal background Continuous low voltage, discontinuous pattern Burst suppression or isoelectric / flat trace

Long-Term Prognosis Usually favorable, though some infants have later difficulties 20% – 35% risk of death or severe disability >75% – 90% risk of death or severe neurodevelopmental disability

Strict Criteria for Therapeutic Hypothermia Eligibility

Therapeutic hypothermia protocols established in landmark randomized clinical trials (NICHD, CoolCap, TOBY) require meeting three specific gating categories (Criteria A, B, and C) strictly within 6 hours of birth :

Criterion A: Gestational Age & Birth Weight

Gestational age ≥ 35 \ge 35 ≥ 35 or ≥ 36 \ge 36 ≥ 36 completed weeks.

Birth weight ≥ 1 , 800 grams \ge 1,800 \text{ grams} ≥ 1 , 800 grams .

Criterion B: Biochemical or Resuscitative Evidence of Acute Perinatal Asphyxia

The infant must meet at least one of the following physiological markers:

Severe Acidosis: Umbilical cord blood gas or any postnatal blood gas (arterial, venous, or capillary) obtained within the first 60 minutes of life demonstrating a pH ≤ 7.00 \le 7.00 ≤ 7.00 OR a base deficit ≥ 16 mmol/L \ge 16 \text{ mmol/L} ≥ 16 mmol/L .

Moderate Acidosis with Resuscitation Burden: If blood gas pH is 7.01 to 7.15 OR base deficit is 10.0 to 15.9 mmol/L , OR if a blood gas is completely unavailable, the patient must meet at least one acute historical/resuscitative criterion:

An acute perinatal sentinel event (e.g., uterine rupture, placental abruption, umbilical cord prolapse, vasa previa hemorrhage, fetal deceleration with non-reassuring fetal heart rate tracing); AND

A 10-minute Apgar score ≤ 5 \le 5 ≤ 5 ; OR

An ongoing need for assisted positive pressure ventilation (endotracheal or mask) initiated at birth and continued for at least 10 consecutive minutes.

Criterion C: Documented Moderate or Severe Encephalopathy

The infant must demonstrate either:

Clinical or electrographic seizures ; OR

Altered level of consciousness (lethargy, stupor, or coma) PLUS documented abnormalities in at least one of the following neurological categories:

  • Abnormal tone (marked hypotonia or flaccidity);
  • Abnormal primitive reflexes (absent or severely depressed suck or Moro);

Autonomic dysfunction (abnormal pupils, bradycardia, or irregular respirations).

Transport Hypothermia Protocols: Active vs. Passive Cooling

Initiating cooling during transport saves vital latent phase time, but must be executed with extreme clinical precision.

Passive Cooling (Uncontrolled Transport)

Passive cooling involves turning off external heat sources (radiant warmers or transport isolette heaters), undressing the infant, unswaddling, and opening incubator access ports to allow ambient radiative and convective heat loss.

Operational Hazards: Highly unpredictable. Ambient vehicle temperatures fluctuating between winter ramps and overheated ambulance cabins cause severe temperature instability. Passive cooling carries a dangerous risk of uncontrolled overcooling ( < 32.0 <32.0 < 32.0 °C) or accidental warming.

Protocol: If passive cooling is used while awaiting specialized transport arrival, the radiant warmer must be turned completely off, but the infant should have a continuous core rectal probe inserted. The warmer should be set to manual mode at low output if core temperature drops toward 33.5 °C.

Active Cooling (Servo-Controlled Transport)

Active cooling employs a specialized, mobile, servo-controlled cooling blanket or fluid-circulating wrap connected directly to a central thermal processing unit.

Servo-Regulation: The system continuously reads core temperature via a rectal or esophageal probe and modulates circulating fluid temperature dynamically (adjusting water between 4 °C and 40 °C) to maintain core body temperature at exactly the programmed setpoint.

Superiority: Active servo-controlled cooling minimizes thermal volatility, completely prevents accidental overcooling, and ensures the neonate arrives at the tertiary hypothermia center within the exact therapeutic range.

Core Temperature Monitoring Standards

Target Core Temperature: 33.5 °C (strict therapeutic window: 33.0 °C to 34.0 °C ).

Monitoring Modality: Continuous core temperature measurement is mandatory. A dedicated rectal temperature probe must be lubricated, inserted gently to a depth of 2 to 3 cm beyond the anal sphincter, and securely taped to the infant's inner thigh. Alternatively, a mid-to-lower esophageal probe placed at the level of the lower third of the esophagus may be utilized in intubated infants.

Contraindicated Methods: Skin probes and intermittent axillary temperature measurements are strictly contraindicated for titration of therapeutic hypothermia. Due to severe cold-induced peripheral vasoconstriction, cutaneous and axillary temperatures read 1.5 °C to 3.0 °C lower than actual central visceral core temperature, leading clinicians to falsely withhold cooling or dangerously overheat an infant.

Overcooling Hazards (<32.0 °C) & Clinical Countermeasures

Allowing core temperature to fall below 32.0 °C introduces severe multisystem physiological hazards: Core Temp <33.0°C ──> Increased risk of arrhythmia & pulmonary hypertension

  • Core Temp <32.0°C ──> Severe bradycardia (<80 bpm), prolonged QT, hypotension
  • Core Temp <30.0°C ──> Ventricular fibrillation, profound coagulopathy, cardiac arrest
  • Physiological Consequences of Overcooling

Cardiovascular Collapse: Physiologic cooling decreases heart rate by approximately 10 to 14 bpm per 1.0 °C drop in core temperature. Cooled neonates normally exhibit heart rates of 80 to 100 bpm. Overcooling ( < 32.0 <32.0 < 32.0 °C) causes profound sinus bradycardia ( < 70 − 80 <70-80 < 70 − 80 bpm), prolongation of PR and QTc intervals, severe myocardial depression, hypotension, and fatal ventricular arrhythmias.

Exacerbation of PPHN: Hypothermia below 33.0 °C causes potent pulmonary vasoconstriction. In asphyxiated neonates with pre-existing parenchymal lung injury, this triggers catastrophic persistent pulmonary hypertension of the newborn (PPHN), severe right-to-left shunting across the ductus arteriosus and foramen ovale, and refractory hypoxemia.

Coagulopathy & Bleeding: Hypothermia inhibits platelet aggregation, impairs the enzymatic clotting cascade, and prolongs PT/INR and PTT. Overcooled neonates suffer pulmonary hemorrhage and extension of intracranial hemorrhages.

Metabolic & Renal Derangements: Decreased tubular function causes severe cold diuresis or acute tubular necrosis with oliguria. Potassium shifts intracellularly during cooling, causing hypokalemia. Rapid rewarming triggers sudden extracellular potassium rebound and lethal hyperkalemia.

Management of Overcooling in Transit

If core temperature falls below 32.5 °C, active cooling must be paused immediately. If temperature falls below 32.0 °C, active controlled rewarming must be initiated at a rate not exceeding 0.5 °C per hour using radiant warmth or incubator air. Rapid rewarming causes abrupt systemic vasodilation, profound hypotension, reduced cerebral perfusion pressure, and secondary brain reperfusion injury.

Shivering Recognition & Management

Shivering is an involuntary physiological thermogenic response to cold stress that completely defeats the neuroprotective goals of therapeutic hypothermia.

Pathophysiology: Shivering increases total metabolic rate by 100% to 300%, markedly elevates oxygen consumption, surges carbon dioxide production, triggers metabolic acidosis, and spikes intracranial pressure (ICP).

Clinical Identification: Shivering in neonates manifests as fine muscular tremors, micro-vibrations palpable over the pectoral and masseter muscles, high-frequency baseline artifact on cardiac EKG monitors, and unexplained elevations in end-tidal CO2.

Pharmacologic Suppression:

Morphine Sulfate: Continuous infusion of 10 to 20 mcg/kg/hr (or intermittent boluses of 0.05 to 0.1 mg/kg IV) provides analgesia, suppresses the hypothalamic shivering setpoint, and reduces metabolic stress.

Fentanyl: 1 to 2 mcg/kg IV as an alternative rapid-acting opioid.

Dexmedetomidine / Sedation: Selective alpha-2 agonists may be titrated under protocolized medical direction.

Neuromuscular Blockade (e.g., Vecuronium): Strictly reserved for intubated, fully ventilated infants with violent shivering refractory to opioids. Paralytics abolish motor shivering but mask clinical seizure activity; continuous electrographic monitoring is mandatory.

  • Clinical Pearl: Rectal Probe Migration & The Overcooling Trap
  • Clinical Pearl: Secure Rectal Probe Placement

A displaced rectal temperature probe is a lethal transport pitfall. If a rectal probe slips partially out of the rectum into ambient cool air, the monitor displays a falsely low reading (e.g., 29.5 °C). An inexperienced clinician might abruptly apply radiant heat, dangerously hypertherming an ischemic brain. Conversely, if an un-servo-controlled baby has a probe migrate into a warm diaper fold, the clinician may apply aggressive cooling, driving real visceral core temperature into lethal ventricular fibrillation territory (<30.0 °C). Always confirm probe insertion depth (2 to 3 cm) and tape securely to the inner thigh before initiating transport.

Loading diagram... HIE Triphasic Progression & Therapeutic Hypothermia Window